Cagrilintide 10mg Vial

Cagrilintide is an innovative, long-acting amylin analogue designed for research purposes, specifically targeting weight management and metabolic health. As a synthetic peptide that mimics the naturally occurring hormone amylin, cagrilintide acts as a nonselective agonist for amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR). This dual-action mechanism promotes appetite suppression, enhances satiety, and supports improved glucose and lipid metabolism, making it a promising candidate for studies related to obesity, type 2 diabetes, and other metabolic disorders. This product, offered in a 10mg lyophilized vial, is intended for laboratory research and is not approved for human consumption.

Discover our high quality collagen peptides and vital proteins collagen peptides, ideal for research on peptides for weight loss, peptides for muscle growth, and peptides for skin, showcasing key collagen peptides benefits through advanced biotech peptides.

• High Purity: Formulated with ≥99% purity, verified through rigorous third-party testing to ensure quality and consistency for research applications.
• Lyophilized Format: Supplied as a freeze-dried powder in a sterile, tamper-proof vial, enhancing shelf life and preserving peptide integrity during storage.
• Long-Acting Design: Engineered to resist enzymatic degradation, cagrilintide offers a prolonged half-life compared to natural amylin, enabling sustained activity in experimental settings.
• Solubility Enhancement: Includes 500mcg–1mg of trehalose per 10mg vial to improve solubility and stability during reconstitution.
• Research Applications: Ideal for preclinical studies investigating appetite regulation, weight loss, glucose metabolism, and related conditions such as obesity and type 2 diabetes.

Cagrilintide mimics the effects of amylin, a pancreatic hormone co-secreted with insulin, which regulates appetite and satiety through actions on the hypothalamus, area postrema, and nucleus of the solitary tract in the brain. By activating AMYR and CTR, cagrilintide reduces food intake, promotes prolonged feelings of fullness, and delays gastric emptying, contributing to decreased caloric consumption. Additionally, it enhances glucose and lipid metabolism, supporting overall metabolic health. Its acylated structure extends its half-life, making it suitable for once-weekly dosing in research protocols, unlike shorter-acting amylin analogues such as pramlintide.

• Molecular Formula: C194H312N54O59S2·xC2H4O2
• Molecular Weight: 4409.01 g/mol
• CAS Number: 1415456-99-3
• PubChem SID: 171397054
• Synonyms: AM833, AT42613
• Appearance: White lyophilized powder
• Storage Conditions: Store at -80°C for up to 2 years or -20°C for up to 1 year in a sealed container, protected from moisture and light, under nitrogen.
• Shipping Conditions: Shipped with blue ice to maintain stability.
• Quantity: 10mg per vial
• Reconstitution: Requires bacteriostatic water, syringes, needles, and alcohol prep pads (not included) for reconstitution and administration in research settings.

Cagrilintide is under investigation for its potential in addressing multiple metabolic conditions:

• Obesity and Overweight: Clinical trials have demonstrated dose-dependent weight loss, with studies reporting up to 10.8% body weight reduction over 26 weeks at higher doses (e.g., 4.5mg). Its ability to suppress appetite and reduce food intake makes it a valuable tool for obesity research.
• Type 2 Diabetes: Cagrilintide is being studied for its effects on blood sugar control, particularly in combination with GLP-1 agonists like semaglutide (CagriSema), showing improved HbA1c levels and weight loss in phase 2 and 3 trials.
• Metabolic Health: Preclinical studies indicate benefits in glucose and lipid metabolism, supporting research into insulin resistance and related conditions.
• Combination Therapies: Cagrilintide’s synergistic effects with GLP-1 agonists (e.g., semaglutide) and dual GLP-1/GIP agonists (e.g., tirzepatide) are being explored for enhanced weight loss and glycemic control.

• Reconstitution: Dissolve the lyophilized powder in bacteriostatic water following standard peptide reconstitution protocols. The inclusion of trehalose aids solubility, but gentle mixing is recommended to avoid degradation.
• Dosing for Research: In preclinical studies, cagrilintide has been administered subcutaneously at doses ranging from 0.3 to 4.5 mg in human trials or 0.1 to 30 nmol/kg in rat models. Researchers should determine appropriate dosing based on study design and objectives.
• Administration: Typically administered via subcutaneous injection in research settings, targeting areas such as the stomach, thighs, or upper arms.
• Safety Note: This product is for research use only and not for human consumption. Handle with care, using appropriate laboratory equipment and protocols to ensure safety and efficacy.

• Store at -80°C for long-term storage (up to 2 years) or -20°C for short-term storage (up to 1 year) in a sealed, dry environment under nitrogen.
• Avoid exposure to moisture and light to maintain peptide stability.
• Handle with sterile equipment to prevent contamination during reconstitution and administration.

• Research Use Only: Cagrilintide is not approved for human use and is intended solely for laboratory research. It is not a dietary supplement, drug, or cosmetic.
• Proper Handling: Only individuals with appropriate training and equipment should handle this product. Improper handling may result in adverse effects or compromised research outcomes.
• Regulatory Status: Cagrilintide is an investigational compound and not FDA-approved. Researchers must comply with all applicable regulations for its use in laboratory settings.